Encefalopatía hepática
Revisado por Dr Toni Hazell, FRCGPÚltima actualización por Dr Philippa Vincent, MRCGPÚltima actualización 10 Sept 2026
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Versión en audio
- Agregar a fuentes preferidas en Google
Profesionales Médicos
Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar el Insuficiencia hepática artículo más útil, o uno de nuestros otros artículos de salud.
Vea también el separado Insuficiencia hepática, Cirrosis y Síndrome hepatorrenal artículos.
¿Qué es la encefalopatía hepática?
Hepatic encephalopathy is defined as a spectrum of neuropsychiatric abnormalities in patients with liver failure, after exclusion of other known brain disease. Hepatic encephalopathy causes a range of symptoms from subtle cognitive changes to severe confusion, personality alterations, disorientation, lethargy, and coma.1
Hepatic encephalopathy is thought to be caused by the accumulation of neurotoxins in patients with liver dysfunction.1
Epidemiología
Studies suggest that hepatic encephalopathy is diagnosed in between 44 and 51% of people with cirrhosis. However, it is thought that up to 80% of people with cirrhosis may have hepatic encephalopathy with more subtle symptoms.1
Causes of hepatic encephalopathy
Hepatic encephalopathy can arise directly from chronic liver disease or from portosystemic shunts where the portal circulation is redirected into the systemic circulation, bypassing the liver and therefore causing a build-up of toxic metabolites.1 Ammonia is the main toxin causing hepatic encephalopathy; other factors include high levels of bile acids in the CSF, manganese accumulation in the basal ganglia, and oxidative stress. Hepatic encephalopathy causes brain cell destruction but brain cell destruction is also one of the underlying mechanisms that causes hepatic encephalopathy - inflammation, in the presence of cirrhosis, appears to lead to tumour necrosis factor (TNF) production which contributes to hepatic encephalopathy development.2
Causes of liver failure include:
Acute liver failure:
Viral hepatitis.
Paracetamol overdose.
Ischaemia eg following sepsis.
Chronic liver failure (cirrhosis):
Alcohol overuse.
Chronic viral hepatitis.
Enfermedad del hígado graso no alcohólico.
In cirrhosis, hepatic encephalopathy is often triggered by a specific precipitant including:
Lesión renal aguda.
.
Sangrado gastrointestinal.
Infección.
Estreñimiento.
Medicamentos sedantes - por ejemplo, opiáceos, benzodiazepinas, antidepresivos y antipsicóticos.
Diuréticos.
Síntomas de la encefalopatía hepática (presentación)
Symptoms include cognitive changes, personality alterations, disorientation, lethargy, and coma. Extrapyramidal signs associated with HE have been clearly documented - these can be episodic and associated with bouts of hepatic encephalopathy; however, they can also be progressive and appear more similar to Parkinson's disease.3
Grading of hepatic encephalopathy - West Haven Criteria1
The West Haven criteria have become the standard criteria to assist in the diagnosis of hepatic encephalopathy:
Grade 0
Minimal hepatic encephalopathy.
Grado 1
Falta trivial de conciencia.
Euforia o ansiedad.
Disminución de la capacidad de atención; rendimiento deteriorado en sumas o restas.
Grado 2
.
Disorientación mínima en tiempo o lugar.
Cambio sutil en la personalidad.
Comportamiento inapropiado.
Grado 3
Sedación hasta semi-estupor, pero receptivo a estímulos verbales.
Confusión.
Desorientación grave.
Grado 4
Coma.
Grading of hepatic encephalopathy - World Health Congress of Gastroenterology criteria
The World Health Congress of Gastroenterology criteria categorise hepatic encephalopathy based on its underlying aetiology: offering a comprehensive approach to the management of hepatic encephalopathy.
Type A (acute): Hepatic encephalopathy associated with acute liver failure, typically with cerebral oedema.
Type B (bypass): Hepatic encephalopathy caused by portal-systemic shunting, without associated intrinsic liver disease.
Type C (cirrhosis): Hepatic encephalopathy in patients with cirrhosis, which is further subdivided into episodic, persistent, and minimal encephalopathy.
Grading of hepatic encephalopathy - covert vs overt
There can be challenges in diagnosing subtle changes in early very mild hepatic encephalopathy. The term covert hepatic encephalopathy can be used to describe minimal hepatic encephalopathy including grades 0 and 1 in the West Haven criteria.
Investigaciones14
LFTs and renal function.
Pruebas psicométricas - estas están siendo cada vez más útiles en el diagnóstico de la encefalopatía hepática mínima.
Los niveles de amoníaco arterial o en suero están elevados y pueden ayudar en el diagnóstico.
Electroencefalograma (EEG): puede mostrar ondas de alta amplitud y baja frecuencia y ondas tripásicas, pero estos hallazgos no son específicos de la encefalopatía hepática.
La resonancia magnética/TAC puede ayudar a descartar otras causas de alteración de la función mental, como lesiones intracraneales.
Las respuestas evocadas visuales muestran patrones clásicos asociados con la encefalopatía hepática.
Diagnóstico diferencial1
Otras causas de encefalopatía, incluyendo:
Intracranial lesions - eg, hemorragia, evento cerebrovascular, tumor.
Infection - eg, meningitis, encefalitis, absceso intracraneal.
Metabolic - eg, hipoglucemia, electrolyte imbalance, anoxia, lesión renal aguda.
Otras causas de hiperamonemia - por ejemplo, ureterosigmoidostomía, trastornos hereditarios del ciclo de la urea.
Toxic - eg, abuso de sustancias, problemas relacionados con el alcohol.
Medicamentos - por ejemplo, sedantes hipnóticos, antidepresivos, agentes antipsicóticos y salicilatos.
Después de una convulsión.
Tratamiento y manejo de la encefalopatía hepática156
Management usually involves ammonia lowering and supportive care.
Methods to combat raised levels of ammonia include lactulose/lactitol and rifaximin.
L-Ornithine L-Aspartate (LOLA) is a drug that can reduce ammonia and has been shown to be beneficial. 2
Trials of other drugs have not shown significant benefit in studies, although further studies are taking place.7
Nutritional support, including regular small meals. Fasting should be avoided. Restriction of protein intake was once thought to be beneficial, but this was not supported by further evidence. Adequate nutrition is essential; in cirrhosis, there is actually an increased requirement for protein.8Some patients experience worsening of their symptoms with meat intake - vegetable proteins are a useful alternative.1
Good hydration and electrolyte correction.
Sedative drugs should be avoided wherever possible. If patients are agitated then a safe environment and restraint is often preferable to sedation.
Other than ammonia-increasing medication, there is no evidence of benefit from other drug treatments.
Surgical procedures to close portosystemic shunts can be effective where the hepatic encephalopathy is caused by a shunt and is not responding to supportive management.
Trasplante de hígado may be offered; where liver transplantation occurs, reversal of the cognitive effects of hepatic encephalopathy may be seen within 5 years.1
Pronóstico de la encefalopatía hepática
Patients with cirrhosis and hepatic encephalopathy have a risk of recurrence. Neurological deficits may persist despite an apparent return to normality; these deficits tend to be worse in patients who have had multiple episodes of hepatic encephalopathy.1
A single episode of overt hepatic encephalopathy increases mortality risk independently of other organ failures. The prognosis tends to be worse in hepatic encephalopathy associated with liver failure. Studies have shown a 44% survival at 12 months and 35%1 survival at 24 months in those needing hospitalisation for their hepatic encephalopathy.
It is advised that all patients with a history of overt hepatic encephalopathy or with minimal hepatic encephalopathy avoid driving.1
Prevención
Rifaximin is recommended by the National Institute for Health and Care Excellence (NICE) as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.9
Lactulose is recommended for all patients with cirrhosis after a single episode of hepatic encephalopathy.1
Patients should adhere to a regulated diet, high in protein, and avoid long periods of fasting. A bedtime snack is often recommended. 1
Actualizaciones exclusivas para profesionales de la salud
Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.
Lecturas adicionales y referencias
- Mandiga P, Kommu S, Bollu PC; Hepatic Encephalopathy.
- Sharma K, Akre S, Chakole S, et al; Hepatic Encephalopathy and Treatment Modalities: A Review Article. Cureus. 2022 Aug 14;14(8):e28016. doi: 10.7759/cureus.28016. eCollection 2022 Aug.
- Hepatic encephalopathy: Part 1, a diagnostic approach; Y Ntuli et al; Frontline Gastroenterology
- ACG Clinical Guideline: Hepatic Encephalopathy; J S Bajaj et al; The American Journal of Gastroenterology
- A practical approach to the diagnosis and management of hepatic encephalopathy; N Reau et al; The American Journal of Medicine
- The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas; D Bellafante et al; Journal of Clinical Medicine
- Hepatic Encephalopathy: Current and Emerging Treatment Modalities; M A Fallahzadeh and R Rahimi; Clinical Gastroenterology and Hepatology
- Cabral CM, Burns DL; Se desacredaron las dietas bajas en proteínas para la encefalopatía hepática: que coman filete. Nutr Clin Pract. 2011 abr;26(2):155-9. doi: 10.1177/0884533611400086.
- Rifaximina para prevenir episodios de encefalopatía hepática manifiesta; NICE Technology Appraisal Guidance, March 2015
Acerca del revisorVer biografía completa

Dr Toni Hazell, FRCGP
MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
La Dra. Toni Hazell se graduó de la Escuela de Medicina del Hospital St. Mary y realizó su VTS en el Hospital Northwick Park.

Pregunta, comparte, conecta.
Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.

¿Te sientes mal?
Evalúa tus síntomas en línea de forma gratuita
Más en neurología
- Agenesia del cuerpo calloso
- Parálisis bulbar y parálisis seudobulbar
- Cheyne-Stokes y patrones anormales de respiración
- Complicaciones de fracturas
- enfermedad de Creutzfeldt-Jakob
- Demencia
- Demencia con cuerpos de Lewy
- Hematoma extradural
- síndrome de Landau-Kleffner
- Esclerosis múltiple
- Síndrome de apnea obstructiva del sueño
- Parkinsonismo y enfermedad de Parkinson
- Ameba de vida libre patógena
- Tumores de la glándula pineal
- Ptosis y retraso del párpado
- Clasificación y manejo del estrabismo (bizquera)
- Toxoplasmosis
- Paraparesia espástica tropical
- Síndrome de Usher
- Demencia vascular
